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ARTICLE OPEN
Asthma prescribing, ethnicity and risk of hospital admission:
an analysis of 35,864 linked primary and secondary care
records in East London
Sally A Hull1,4, Shauna McKibben2,4, Kate Homer1, Stephanie JC Taylor2, Katy Pike3 and Chris Grifﬁths2
Inappropriate prescribing in primary care was implicated in nearly half of asthma deaths reviewed in the UK’s recent National
Review of Asthma Deaths. Using anonymised EMIS-Web data for 139 ethnically diverse general practices (total population 942,511)
extracted from the North and East London Commissioning Support Unit, which holds hospital Secondary Uses Services (SUS)–linked
data, we examined the prevalence of over-prescribing of short-acting β2-agonist inhalers (SABA), under-prescribing of inhaled
corticosteroid (ICS) inhalers and solo prescribing of long-acting β2-agonists (LABA) to assess the risk of hospitalisation for people
with asthma for 1 year ending August 2015. In a total asthma population of 35,864, multivariate analyses in adults showed that the
risk of admission increased with greater prescription of SABA inhalers above a baseline of 1–3 (4–12 SABA: odds ratio (OR) 1.71; 95%
conﬁdence interval (CI) 1.20–2.46, ⩾ 13 SABA: OR 3.22; 95% CI 2.04–5.07) with increasing British Thoracic Society step (Step 3: OR
2.90; 95% CI 1.79–4.69, Step 4/5: OR 9.42; 95% CI 5.27–16.84), and among Black (OR 2.30; 95% CI 1.64–3.23) and south Asian adult
populations (OR 1.83; 95% CI 1.36–2.47). Results in children were similar, but risk of hospitalisation was not related to ethnic group.
There is a progressive risk of hospital admission associated with the prescription of more than three SABA inhalers a year. Adults
(but not children) from Black and South Asian groups are at an increased risk of admission. Further work is needed to target care for
these at-risk groups.
npj Primary Care Respiratory Medicine (2016) 26, 16049; doi:10.1038/npjpcrm.2016.49; published online 18 August 2016
INTRODUCTION
Frequent use of short-acting β2-agonist (SABA) inhaler medication
is a key indicator of poor asthma control,1,2 a risk factor for
asthma exacerbations3 and a potentially modiﬁable risk factor
for asthma-related death.4,5 Clinical guidelines recommend that
those using more than one SABA canister (200 actuations) per
month should have an early clinical review.5,6 The UK National
Review of Asthma Deaths (NRAD)4 identiﬁed poor prescribing
practice and a failure by clinicians to adhere to British Thoracic
Society (BTS)/SIGN asthma guidelines. In 39% of the 195
asthma deaths reviewed,412 SABA inhalers had been prescribed
in the previous year; 450 SABA inhalers had been prescribed in
4% of cases; and in 3% of cases long-acting β2-agonist (LABA)
monotherapy was prescribed without inhaled corticosteroid (ICS)
preventer treatment.4
Asthma morbidity disproportionately affects people from
ethnic minority backgrounds.7 Often concentrated in inner-city
areas,8,9 ethnic minorities often have poorer continuity with
healthcare providers,10 less familiarity with primary
healthcare practitioners11 and are more likely to present to
Accident and Emergency Departments (AED) as a primary
source of care.12 In 1998, UK hospitalisation rates for asthma
in adults and children of black and south Asian origin were
found to be higher than in the white British population.13
Recent data from Scotland showed an increased risk of
hospitalisation for Pakistani and Indian adults14 but did not
provide analyses for ethnic minority children. Figures for UK
emergency asthma admission rates showed that the East
London boroughs included in our study all had crude admission
rates above the average for London (1.02/1000 population)
in 2012–13.15
Studies suggest that differences in asthma medication use
may contribute to asthma morbidity in ethnic minority
populations,16,17 yet these groups are often under-represented
in asthma research.
Inappropriate use of asthma medications has been reported as
a major contributor to uncontrolled asthma in inner-city
populations,18,19 particularly in children from inner-city areas
who are more likely to overuse SABA on a daily basis18 and are the
least likely to receive adequate guideline-based therapy17,20 or
specialty asthma care.21–23 In US research by Crocker et al.18
and Butz et al.,24 SABA use was high among inner-city
children, with hospitalisation for asthma ﬁve times more likely
in high SABA users than in low-to-moderate users,24 whereas
twice as many black children had asthma-related AED visits
(39 vs 18%) and hospitalisations (12 vs 5%,) compared with
white children.18
To examine the prevalence of sub-optimal prescribing and
differences in asthma outcomes, this study linked primary and
secondary care records from a large multi-ethnic inner-city
population of patients aged 5–75 years with asthma, to address
the following questions:
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● How common is the excessive prescription of SABA inhalers for
people with asthma?
● How common is the prescription of LABA inhalers without
co-prescription of an ICS?
● Is excessive SABA prescribing and solo LABA prescribing
associated with adverse morbidity, including hospitalisation?
● Which population groups are at an increased risk of
hospitalisation with asthma?
RESULTS
Among our study population of 35,864 cases, 67% of the child and
adolescent groups and 46% of the adult groups were of Black or
South Asian ethnicity (Table 1). Smoking rates for adults with
asthma (20%) are similar to that for the whole East London
population.25 Over 93% of patients had an asthma review
recorded and 82% had an asthma management plan. BTS asthma
treatment step was recorded for 86%. The overall annual
non-elective admission episode rate for asthma was 2.4/100
population. Crude admission episode rates were highest among
the youngest group (Table 1).
Excess SABA prescribing
Among the total asthma population, 10.2% (3,671/35,864) were
prescribed412 SABA inhalers a year (Table 1). These high rates of
SABA prescribing were observed among 5.9% of children and
adolescents, and in 13.6% of adults.
Treatment by SABA alone
Table 2 shows asthma severity, primary care management and
hospital admissions among the 8,227 cases (22.8%) in whom SABA
Table 1. Characteristics of the study population (N= 35,864)
Total Children Adolescents Adult Mature adults
Age (years) All N (%) 5–11 N (%) 12–17 N (%) 18–54 N (%) 55–75 N (%)
35,864 (100.0) 3,585 (10.0) 3,269 (9.1) 21,581 (60.2) 7,429 (20.7)
Gender
Female 19,113 (53.3) 1,353 (37.7) 1,309 (40.0) 11,891 (55.1) 4,560 (61.4)
Ethnicity
White 14,083 (39.3) 650 (18.1) 547 (16.7) 9,423 (43.7) 3,463 (46.6)
South Asian 11,921 (33.2) 1,634 (45.6) 1,554 (47.5) 6,442 (29.9) 2,291 (30.8)
Black 5,925 (16.5) 676 (18.9) 698 (21.4) 3,487 (16.2) 1,064 (14.3)
Other 1,522 (4.2) 161 (4.5) 123 (3.8) 879 (4.1) 359 (4.8)
Unknowna 2,413 (6.7) 464 (12.9) 347 (10.6) 1,350 (6.3) 252 (3.4)
Clinical measures
Asthma review 33,531 (93.5) 3,203 (89.3) 3,149 (96.3) 19,925 (92.3) 7,254 (97.6)
Asthma management plan 29,352 (81.8) 2,689 (75.0) 2,838 (86.8) 17,246 (79.9) 6,579 (88.6)
Asthma step recorded 30,886 (86.1) 2,817 (78.6) 2,932 (89.7) 18,204 (84.4) 6,933 (93.3)
Inhaler technique checked 30,201 (84.2) 2,548 (71.1) 2,880 (88.1) 17,791 (82.4) 6,982 (94.0)
Flu immunisationb 20,458 (57.0) 1,680 (46.9) 1,517 (46.4) 11,251 (52.1) 6,010 (80.9)
Currently smoking 6,188 (17.3) (0.0) 52 (1.6) 4,938 (22.9) 1,198 (16.1)
COPD diagnosis 1,613 (4.5) 2 (0.1) 3 (0.1) 396 (1.8) 1,212 (16.3)
Asthma severityc
Mild intermittent asthma—Step 1 7,660 (24.8) 847 (30.1) 975 (33.3) 4,746 (26.1) 1,092 (15.8)
Regular preventer therapy—Step 2 16,863 (54.6) 1,780 (63.2) 1,717 (58.6) 9,812 (53.9) 3,554 (51.3)
Initial add-on therapy—Step 3 5,595 (18.1) 171 (6.1) 221 (7.5) 3,228 (17.7) 1,975 (28.5)
Persistent poor control—Step 4 718 (2.3) 19 (0.7) 18 (0.6) 394 (2.2) 287 (4.1)
Severe asthma—Step 5 50 (0.2) (0.0) 1 (0.0) 24 (0.1) 25 (0.4)
Healthcare resource use
Count GP consultations (median) 158,873 (3) 10,571 (2) 8,428 (2) 93,322 (3) 46,552 (5)
Count IP episodes (median) 872 (0) 131 (0) 55 (0) 498 (0) 188 (0)
Crude IP episode, rate per 100 population 2.43 3.65 1.68 2.31 2.53
SABA inhalers prescribed
0 1,709 (4.8) 72 (2.0) 61 (1.9) 1,135 (5.3) 441 (5.9)
1–3 15,611 (43.5) 1,557 (43.4) 1,648 (50.4) 10,408 (48.2) 1,998 (26.9)
4–12 14,873 (41.5) 1,759 (49.1) 1,355 (41.4) 8,125 (37.6) 3,634 (48.9)
13+ 3,671 (10.2) 197 (5.5) 205 (6.3) 1,913 (8.9) 1,356 (18.3)
Total ICS+COMBI inhalers prescribed
0 8,354 (23.3) 817 (22.8) 915 (28.0) 5,482 (25.4) 1,140 (15.3)
1–9 22,340 (62.3) 2,567 (71.6) 2,134 (65.3) 13,579 (62.9) 4,060 (54.7)
10+ 5,170 (14.4) 201 (5.6) 220 (6.7) 2,520 (11.7) 2,229 (30.0)
Abbreviations: COMBI, combination inhalers (ICS and Long-acting β2-agonist); COPD, chronic obstructive pulmonary disease; GP, general practitioner; ICS,
inhaled corticosteroid; IP, inpatient; SABA, short-acting β2-agonist.
aUnknown ethnic group=not stated code or missing.
bFlu immunisation in the past year.
cAsthma step as a proportion of total with asthma step recorded.
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inhalers were prescribed as the sole treatment. BTS asthma
treatment step 1 was recorded in 68% of cases, and in 87% of
cases an asthma review was carried out in the previous year.
Within this group, 3.5% (285 cases) were prescribed 412 SABA
inhalers a year. The crude asthma admission rate was 0.67%.
Treatment by ICS or COMBI with SABA
The majority (27,637, 77%) of the population with asthma was
prescribed ICS or COMBI treatment, as well as SABA inhalers.
Among these, 20,884 (76%) were prescribed fewer than 10 ICS
canisters a year, which we considered a marker of sub-optimal
preventer treatment.4
Table 3 shows asthma severity, primary care management and
hospital admissions among the 20,884 cases who were prescribed
o10 ICS or combination inhalers—ICS and Long-acting β2-agonist
(COMBI) inhalers a year. Within this group, BTS asthma treatment
step 2 was recorded in 65%, and in 95% of cases an asthma review
was carried out in the previous year; 5.5% of cases were prescribed
412 SABA canisters a year. The crude hospital admission episode
rate for asthma rises from 1.3 to 7.5 per 100 population as the
number of SABA inhalers prescribed rises from 1–3 to 13+ a year.
The greatest number of emergency hospital admissions for
asthma (447 admissions) occurs in this group of people prescribed
o10 ICS inhalers a year. Among this group, we estimate a number
needed to treat (NNT) of 16 to potentially reduce the 7.5% risk of
admission in the high SABA use group to the 2% risk of admission
seen in those using ⩽ 12 SABA inhalers.
Use of LABA without concomitant inhaled steroids
Among the asthma population (excluding all those with a read
coded COPD diagnosis), 0.3% (105) of the cases had a LABA
prescribed without ICS. Asthma reviews were completed for 88%
of cases, and there were no admissions among this group
(Supplementary Appendix 1).
Risk of emergency hospital admission
Multivariate analyses (Table 4) showed that in both children and
adults the risk of admission rose steadily when SABA prescribing
Table 2. Severity and clinical management of asthma population prescribed SABA alone, by number of SABA inhalers (N= 8,227)
Total N (%) 1–3 N (%) 4–12 N (%) 13+N (%)
8,227 (100.0) 5,888 (71.6) 2,054 (25.0) 285 (3.5)
Clinical measures
Asthma review 7,176 (87.2) 4,963 (84.3) 1,936 (94.3) 277 (97.2)
Asthma management plan 5,875 (71.4) 3,977 (67.5) 1,653 (80.5) 245 (86.0)
Asthma step recorded 6,077 (73.9) 4,076 (69.2) 1,740 (84.7) 261 (91.6)
Asthma severitya
Step 1 4,106 (67.6) 2,901 (71.2) 1,076 (61.8) 129 (49.4)
Step 2 1,683 (27.7) 1,039 (25.5) 543 (31.2) 101 (38.7)
Step 3 270 (4.4) 133 (3.3) 111 (6.4) 26 (10.0)
Step 4/5 18 (0.3) 3 (0.1) 10 (0.6) 5 (1.9)
Healthcare resource use
Count IP episodes 55 20 33 2
Crude IP episode, rate per 100 population 0.67 0.34 1.61 0.70
Abbreviations: IP, inpatient; SABA, short-acting β2-agonist.
aAsthma step % as a proportion of total with asthma step recorded.
Table 3. Severity and clinical management of asthma population prescribed 1–9 ICS+COMBI per year, by number of SABA inhalers (N= 20,884)
Total N (%) 1–3 N (%) 4–12 N (%) 13+N (%)
20,884 9,451 (45.3) 10,285 (49.3) 1,148 (5.5)
Clinical measures
Asthma review 19,787 (94.8) 8,739 (92.5) 9,919 (96.4) 1,129 (98.3)
Asthma management plan 17,471 (83.7) 7,603 (80.5) 8,848 (86.0) 1,020 (88.9)
Asthma step recorded 18,498 (88.6) 7,986 (84.5) 9,435 (91.7) 1,077 (93.8)
Asthma severitya
Step 1 3,060 (16.5) 1,621 (20.3) 1,313 (13.9) 126 (11.7)
Step 2 11,929 (64.5) 5,279 (66.1) 6,085 (64.5) 565 (52.5)
Step 3 3,153 (17.1) 1,023 (12.8) 1,831 (19.4) 299 (27.8)
Step 4/5 356 (1.9) 63 (0.8) 206 (2.2) 87 (8.1)
Healthcare resource use
Count IP episodes 447 122 239 86
Crude IP episode, rate per 100 population 2.14 1.29 2.32 7.49
Abbreviations: COMBI, combination inhalers (ICS and Long-acting β2-agonist); ICS, inhaled corticosteroid; IP, inpatient; SABA, short-acting β2-agonist.
aAsthma step % as a proportion of total with asthma step recorded.
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exceeded 1–3 inhalers a year, and when BTS asthma treatment
step was42. Children and women had a higher risk of admission.
Among adults, but not children, the risk of admission was
increased for those with Black or south Asian ethnicity in
comparison with White groups. Further analysis by ethnicity did
not suggest differences in primary care management or prescrib-
ing to account for these ﬁndings (Table 5).
Supplementary Appendix 2 details the characteristics of the 410
individuals who accounted for 872 episodes of asthma admission.
These reﬂect the factors identiﬁed in the multivariate model, and
the proportions of asthma reviews and management plans did not
differ from the whole asthma population.
DISCUSSION
Main ﬁndings
We report the ﬁrst UK population–based analysis of prescribing
and risk of hospitalisation in a multi-ethnic population. Among the
study population of 35,864 people with asthma, the results
showed high levels of recorded asthma reviews (93%) compared
with the Quality and Outcomes Framework (QOF) data for England
2014–15, which report that 76% of patients on asthma registers
received an asthma review in the previous 12 months.26 Our
results also showed that 82% of the population received asthma
management plans, suggesting a high level of guideline-based
primary care within the East London asthma population.
It is chastening to observe that among adults with asthma the
prevalence of smoking is the same as the general population.
This suggests that although smoking status for those with asthma
is well-recorded, smoking cessation interventions in primary care
are either under-utilised or insufﬁcient to support people with
asthma to stop smoking.
Table 4. Multivariate model for risk of admission for children
(5–17 years) and for adults (18–75 years)
Children (5–17) Na= 6,853 Adults (18–75) Na= 28,992
OR 95% CI P value OR 95% CI P value
Gender
Male (ref) 1 1
Female 1.36 (0.98–1.89) 0.07 1.34 (1.03–1.75) 0.03
Age 0.85 (0.81–0.90) o0.00 0.98 (0.97–0.99) 0.00
Ethnicityb
White (ref ) 1 1
South
Asian
1.47 (0.83–2.62) 0.19 1.83 (1.36–2.47) o0.00
Black 1.21 (0.61–2.40) 0.58 2.30 (1.64–3.23) o0.00
Flu immunisationc
No (ref ) 1 1
Yes 1.01 (0.75–1.38) 0.93 1.03 (0.74–1.43) 0.85
Currently smoking
No (ref ) NA 1
Yes NA NA NA 0.83 (0.61–1.12) 0.23
COPD diagnosis
No (ref ) NA 1
Yes NA NA NA 0.99 (0.59–1.68) 0.98
SABA inhalers prescribed
1–3 (ref) 1 1
0 1.03 (0.25–4.36) 0.96 0.81 (0.37–1.78) 0.60
4–12 1.66 (1.13–2.43) 0.01 1.71 (1.20–2.46) o0.00
13+ 4.09 (2.01–8.34) o0.00 3.22 (2.04–5.07) o0.00
Asthma severity
Step 1 (ref ) 1 1
Step 2 1.30 (0.76–2.24) 0.33 1.24 (0.79–1.97) 0.35
Step 3 2.73 (1.41–5.28) o0.00 2.90 (1.79–4.69) o0.00
Step 4/5 5.54 (1.50–20.51) 0.01 9.42 (5.27–16.84) o0.00
GP consultation rate per patient
0–1 (ref) 1 1
2–6 1.32 (0.92–1.90) 0.13 1.59 (0.99–2.57) 0.06
46 2.58 (1.43–4.66) o0.00 2.80 (1.70–4.63) 0.00
Adjusted for IMD2010 quintile, total ICS+COMBI inhalers and practice
clustering.
Abbreviations: CI, conﬁdence Interval; COMBI, combination inhalers
(ICS and long-acting β2-agonist); COPD, chronic obstructive pulmonary
disease; ICS, inhaled corticosteroid; OR, odds ratio; NA, not applicable;
SABA, short-acting β2-agonist.
aN= cases contributing to the model.
b'Other' and 'unknown' ethnicity categories not shown.
cFlu immunisation in the past year.
Table 5. Characteristics of major ethnic groupsa for all adults in the
asthma population (N= 29,010), percentages shown
Totala% White % South
Asian %
Black %
Number 29,010 12,886 8,733 4,551
Gender
Female 56.7 56.9 53.2 63.4
Age bands
18–54 74.4 73.1 73.8 76.6
55–75 25.6 26.9 26.2 23.4
Clinical measures
Asthma review 93.7 92.4 95.8 95.6
Asthma management plan 82.1 78.9 88.5 84.6
Asthma step recorded 86.6 84.7 90.5 89.0
Inhaler technique checked 85.4 83.1 89.9 89.0
Flu immunisationb 59.5 55.0 70.0 56.7
Currently smoking 21.2 27.0 14.5 18.3
COPD diagnosis 5.5 8.6 3.3 2.7
Asthma severityc
Step 1 23.2 22.8 22.2 24.1
Step 2 53.2 50.1 56.2 56.7
Step 3 20.7 23.4 19.4 17.1
Step 4/5 2.9 3.7 2.2 2.1
SABA inhalers prescribed
0 5.4 5.5 5.7 4.6
1–3 42.8 42.1 40.4 45.0
4–12 40.5 40.0 42.2 41.4
13+ 11.3 12.4 11.7 9.0
Total ICS+COMBI inhalers prescribed
0 22.8 23.7 19.8 22.7
1–9 60.8 59.4 62.2 63.6
10+ 16.4 16.9 18.0 13.7
Healthcare resource use
Count IP episodes 686 271 246 116
Crude IP episode, rate per
100 population
2.36 2.10 2.82 2.55
Abbreviations: COMBI, combination inhalers (ICS and long-acting
β2-agonist); COPD, chronic obstructive pulmonary disease; ICS, inhaled
corticosteroid; IP, inpatient; SABA, short-acting β2-agonist.
a'Other' and 'unknown' ethnicity categories not shown.
bFlu immunisation in the past year.
cAsthma step % as a proportion of total with asthma step recorded.
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Prescribing for asthma
Of those prescribed SABA as the sole treatment, 3.5% of cases
were prescribed 412 SABA in the previous year. In all, 95% of
cases were documented as BTS asthma treatment step 1 or 2,
suggesting that those treated with SABA alone had milder asthma
and are at a lower risk for admission. However, it is likely that
some cases in this group would beneﬁt from additional ICS
treatment.
The greatest burden of emergency hospital admission for
asthma (447 admissions) occurred among the population
requiring inhaled steroids but prescribed less than 10 ICS inhalers
a year. In this group, rising numbers of prescribed SABA canisters
is a clear marker of risk for hospital admission.
In a small number of cases (0.3%), LABAs were prescribed
without an ICS. LABAs have the potential to increase the risk of
asthma mortality when used by patients with unstable asthma
without concomitant ICS therapy or scheduled medical review;27
however, there is no evidence of an increased risk of asthma
mortality with combination ICS/LABA inhaler therapy in asthma.28
Interpretation of ﬁndings in relation to previously published work
Reports from North America suggest that increasing use of more
than three SABA inhalers per year is associated with an increased
risk of asthma-related hospitalisation.1,24,29–33 In the absence of
similar studies in the UK, our results conﬁrm that using more than
three SABA inhalers per year is an independent risk factor for
asthma-related hospitalisation in both children and adults.
Previous studies12,18,34 have found that children from ethnic
minority groups have higher rates of admission than those in the
White population, with the most recent UK data reported in
1998.13 We did not observe this difference, suggesting that all
children in East London get equal access to primary asthma care
management. A recent report on ethnic variations in asthma
hospital admission, re-admission and deaths in Scotland14
observed a modestly increased rate of hospital admission for
asthma among the Pakistani and Indian populations, but not in
those of African ethnicity. In contrast, we ﬁnd that adults from
Black or south Asian ethnicity have a twofold risk of admission in
comparison with those of White background. We ﬁnd no
indication that these groups have more severe asthma, or have
different patterns of primary care management or prescribing.
This suggests that there may be differences in health-seeking
behaviour or self-management related to culture, language or
asthma understanding, which we are not able to capture in a
database study.
Strengths and limitations of this study'
These results are based on asthma cases from a population of
almost one million GP-registered patients in East London, linked
to ‘real-time’ hospital activity data. The advantage of this
contiguous practice population data set is that it avoids the
selective bias of practice ‘opt-in’. Results from this study will be
generalisable to other inner urban populations in the UK. With
over 93% ethnicity recording in this urban, multi-ethnic
population, we are able to explore the contribution of ethnicity
and deprivation alongside other established risk factors for
asthma admission.
The prescribing data are based on electronic prescriptions
issued by GPs; hence, this will include non-dispensed items
(lost, unused, incorrect) in contrast to studies elsewhere,
which have used dispensing data.1,24,29–32 In the absence of
medication-dispensing data linked with medical records in the UK,
patient-level primary care prescribing data can be used to assess
medication usage35 and is a useful predictor of dispensing-based
adherence.36 In addition, we were not able to link oral steroid use
for asthma exacerbations, or capture ‘rescue steroid courses’
initiated by patients.
Although we obtained Secondary Uses Services (SUS) data on
asthma-related hospitalisations, we were unable to examine
asthma attendances at AED because of the low rates of AED
problem coding in the linked data set (see Materials and methods
section).
Implications for future research, policy and practice
The electronic surveillance of prescription reﬁll frequency in
primary care has been recommended to alert clinicians to patients
being prescribed excessive quantities of SABAs4 to allow for more
frequent monitoring of those at risk of exacerbation. Computer
decision support systems, which include electronic alerts, are
increasingly used globally in the policy drive to improve
prescribing safety. Those with asthma who are under-prescribed
ICS and over-prescribed SABA account for the majority of
hospital admissions. We recommend that electronic surveillance
of prescribing be introduced in primary care practices to
identify this at-risk population. Previous research shows that
disproportionately few patients are responsible for a large
component of total asthma direct medical costs;33 therefore, the
identiﬁcation of high-risk asthma populations might allow for
targeted interventions to improve asthma control and reduce
healthcare resource use.
Despite guideline recommendations that LABA should be
prescribed in ﬁxed-dose-combination ICS/LABA inhalers for
the treatment of asthma,5,6 our results show that clinicians
do not always adhere to guidelines. We support previous
recommendations37 suggesting practice strategies which detect
and feedback to clinicians inappropriate LABA monotherapy.
Furthermore, LABA/ICS therapy should only be available for
prescription in a single device combination inhaler for the
management of asthma.
Conclusions
In this study, we identiﬁed a twofold risk in hospital admissions for
asthma in adults of ethnic minority backgrounds but not in
children and adolescents of ethnic minority backgrounds. We
found no variation in the prescribing and management of ethnic
minority populations to account for these differences. A variety of
possible explanations have been suggested for the observed
ethnic inequalities in the burden of asthma,38 including lifestyle
and environment, culture, communication issues and the nature
of doctor–patient interactions. Further research addressing the
social, cultural and psychological issues experienced by ethnic
minorities is necessary to explain ethnic variations in asthma
hospitalisations and to effect change in asthma outcomes.
MATERIALS AND METHODS
This study was set in the three geographically contiguous East London
clinical commissioning groups (CCGs) of Newham, Tower Hamlets and City
and Hackney, with a combined GP-registered population of 942,511 in
2015. In the 2011 UK census, 48% of the population in these three CCGs
was recorded to be of non-White ethnic origin and among the eight most
socially deprived localities in Britain.39
Data sources
In August 2015, anonymised demographic and clinical data were extracted
from the North and East London Commissioning Support Unit (NELCSU),
which holds EMIS-Web primary care data linked to hospital SUS data.40
Data were obtained for all patients aged 5–75 years: children (5–11 years),
adolescents (12–17 years), adults (18–54 years) and mature adults (55–75
years) currently registered with 139/140 general practices in the area.
Data were extracted on secure N3 terminals using SQL Server Management
Studio (2014), which interfaces with the CSU databases. All data were
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anonymous and managed according to UK NHS information governance
requirements.
Clinical and prescribing variables
The study population was identiﬁed using the read code set for asthma
used by the UK QOF. Among 942,511 registered patients, we identiﬁed
35,864 cases, aged 5–75 years, with a recorded diagnosis of asthma, and
who were prescribed ⩾ 1 inhaled asthma medication in the previous
12 months. This formed our study population for analysis.
We extracted data on clinical variables, including smoking status,
inﬂuenza immunisation and the presence of COPD, and aspects of
asthma care, including the BTS asthma treatment steps, the presence
of asthma review, inhaler technique and asthma management plans.
For all asthma care variables, the most recent value in the previous year
(August 2014–August 2015) was used. Prescribing data included all inhaled
asthma medications issued in the previous year. Data were converted to
annual numbers of inhalers issued in the following therapeutic categories,
SABA, LABA, ICS and COMBI.
Ethnicity and demographic data
Self-reported ethnicity was recorded at the practice during registration or
routine consultation. Ethnic categories are based on the UK 2011 census
and for this study were condensed into three major categories:
White (British, Irish, other White), Black (Black African, Black Caribbean,
Black British, other Black and mixed Black) and South Asian (Bangladeshi,
Pakistani, Indian, Sri Lankan, British Asian, other South Asian or mixed
Asian). The index of multiple deprivation (IMD2010) score (derived
from census variables and linked to patient place of residence) was used
as a measure of social deprivation, categorised in quintiles of the study
population.41
Health Service use Primary care consultation data for the previous year
were extracted as contacts with General Practitioners either in the surgery
or at home, and telephone contacts. Non-elective inpatient hospital
admissions where asthma was recorded as the primary cause were
collected using International Classiﬁcation of Diseases (ICD-10) codes for
Asthma (J45) and Acute Severe Asthma (J46).42 Data were extracted for all
AED visits for the study population in the previous year. However, the
reason for AED attendance was missing in 495% of instances; hence,
these data were not used in the analysis.
Statistical analysis
Statistical analyses were performed using Stata version 12 (StataCorp LLP,
College Station, TX, USA). On the basis of advice from community
pharmacists and CCG-prescribing advisors, inhaler prescriptions were
examined, and those patients with more than four inhalers of any one type
prescribed on a single date were excluded from the analysis as likely to
represent prescribing errors. This constituted 289/36,153 (0.8%) of cases.
To examine the contribution of factors to risk of admission with asthma,
multivariate models were constructed using potential explanatory
variables (Table 1). We examined collinearity, ﬁnding a signiﬁcant
association (Spearman’s ρ= 0.6) between the prescribing rates of SABA
and ICS+COMBI. As potentially important clinical predictors of hospital
admission, both were included in the ﬁnal model.
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